logo
Plus   Neg
Share
Email

AbbVie: FDA Places Partial Clinical Hold On Clinical Trials Of Venetoclax In Treatment Of Multiple Myeloma

AbbVie (ABBV) said the U.S. Food and Drug Administration has placed a partial clinical hold on all clinical trials evaluating venetoclax or VENCLEXTA/VENCLYXTO for the investigational treatment of multiple myeloma.

The partial clinical hold follows a review of data from the ongoing Phase 3 BELLINI trial (M14-031), a study in relapsed/refractory multiple myeloma, in which a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial.

As a result of this action, no new patients should be enrolled in any studies of venetoclax for multiple myeloma until a further analysis of the data is completed. Patients who are currently enrolled in studies and receiving benefit from the therapy may continue with treatment, after consultation with their physician, the company said.

This action does not impact any of the approved indications for venetoclax, such as chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML), and is limited to investigational clinical trials in multiple myeloma. AbbVie remains confident in the benefit/risk profile of venetoclax in those approved indications.

Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Business software giant Oracle Corp. (ORCL), Wednesday reported a fourth-quarter profit and revenues that trumped Wall Street estimates, reflecting growth in cloud services revenues. Redwood Shores, California-based Oracle reported fourth-quarter profit of $3.74 billion or $1.07 per share, up from... Panera is revamping its menu and has introduced 10 new dinner items to its list as the sandwich chain wants its customers to visit them for even dinner. Panera on Wednesday announced that it is testing an entirely new dinner menu featuring items such as flatbreads, bowls, meatier sandwiches as well... Ann Marie Buerkle, the acting chairwoman of the Consumer Product Safety Commission, has announced her decision to step down as the head of the federal regulatory agency at the end of her term in October. "I have notified the White House that I am withdrawing my nominations to serve as Chairman of...
Follow RTT